Publications by authors named "Karla Hurt"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

735

Total Likes

577

Extended Reach

3,696,525

Social Features

199
H
HFpEF-ABA score is a more useful enrichment tool than natriuretic peptides in heart failure with preserved ejection fraction.
Barry A Borlaug, Michael R Zile, Christopher M Kramer, Sheldon E Litwin, Wenyu Ye, Karla Hurt

Eur Heart J· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial.
Carolyn S P Lam, Angel Rodriguez, Ali Aminian, Ele Ferrannini, Hiddo J L Heerspink, Karla Hurt

Obesity (Silver Spring)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT Trial.
Barry A Borlaug, Michael R Zile, Christopher M Kramer, Wenyu Ye, Yang Ou, Karla Hurt

J Am Coll Cardiol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity.
Michael R Zile, Barry A Borlaug, Christopher M Kramer, Seth J Baum, Sheldon E Litwin, Karla C Hurt

Circulation· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial.
Barry A Borlaug, Michael R Zile, Christopher M Kramer, Seth J Baum, Karla Hurt

Nat Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy.
Christopher M Kramer, Barry A Borlaug, Michael R Zile, Dustin Ruff, Joseph M DiMaria, Karla C Hurt

J Am Coll Cardiol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR, HER2-Advanced Breast Cancer.
Patrick Neven, Stephen R D Johnston, Masakazu Toi, Joohyuk Sohn, Kenichi Inoue, Karla C Hurt

Clin Cancer Res· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
Patrick Neven, Hope S Rugo, Sara M Tolaney, Hiroji Iwata, Masakazu Toi, Karla C Hurt

Breast Cancer Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER.
Jonathan W Goldman, Julien Mazieres, Fabrice Barlesi, Konstantin H Dragnev, Marianna Koczywas, Karla C Hurt

Front Oncol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
George W Sledge, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue, Karla Hurt

JAMA Oncol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.
Thomas Wehler, Michael Thomas, Christian Schumann, Joaquim Bosch-Barrera, Nuria Viñolas Segarra, Karla Hurt

Lung Cancer· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients.
Berta Laquente, Jose Lopez-Martin, Donald Richards, Gerald Illerhaus, David Z Chang, Karla Hurt

BMC Cancer· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors.
Emiliano Calvo, Fadi Braiteh, Daniel Von Hoff, Robert McWilliams, Carlos Becerra, Karla Hurt

Oncology· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy.
Jonathan W Goldman, Peipei Shi, Martin Reck, Luis Paz-Ares, Andrew Koustenis, Karla C Hurt

Clin Lung Cancer· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer.
Paweł Wiechno, Bradley G Somer, Begoña Mellado, Piotr L Chłosta, José Manuel Cervera Grau, Karla Hurt

Eur Urol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer.
Glen J Weiss, Ross C Donehower, Tara Iyengar, Ramesh K Ramanathan, Karen Lewandowski, Karla Hurt

Invest New Drugs· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Withholding/withdrawal of life support in trauma patients: is there an age bias?
Brian R Plaisier, Paul A Blostein, Karla J Hurt, Mark A Malangoni

Am Surg· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis